HHMI
JAZZ icon

Howard Hughes Medical Institute’s Jazz Pharmaceuticals JAZZ Stock Holding History

Howard Hughes Medical Institute’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-332
Closed -$52K – 78
2017
Q2 		$52K Buy
+332
New +$50.8K 0.01% 149
2017
Q1 		– Sell
-1,252
Closed -$137K – 157
2016
Q4 		$137K Buy
1,252
+332
+36% +$37K 0.03% 128
2016
Q3 		$112K Buy
+920
New +$124K 0.03% 136

Other funds holding JAZZ

PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
SIG
Senator Investment Group New York $2.18B AUM 58.56% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Howard Hughes Medical Institute's JAZZ Position: Q3 2017 in Review

Howard Hughes Medical Institute sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2017, closing a stake of 332 shares — an estimated $52K sold.

Howard Hughes Medical Institute first reported a position in JAZZ in Q3 2016 and held it in 3 quarters. The position peaked at $137K in Q4 2016. 303 funds tracked by Wall St. Rank hold JAZZ as of Q3 2017.

  • Howard Hughes Medical Institute reported no remaining Jazz Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Howard Hughes Medical Institute sold 332 Jazz Pharmaceuticals shares in Q3 2017, an estimated $52K.
  • Howard Hughes Medical Institute first reported a position in Jazz Pharmaceuticals in Q3 2016 and held it in 3 quarters.
  • Howard Hughes Medical Institute's Jazz Pharmaceuticals position peaked at $137K in Q4 2016.
  • 303 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2017.

Based on Howard Hughes Medical Institute's 13F filing for Q3 2017, filed 2 Nov 2017.